{"nctId":"NCT00651118","briefTitle":"A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","startDateStruct":{"date":"2008-03"},"conditions":["Seasonal Allergic Rhinitis"],"count":832,"armGroups":[{"label":"fluticasone propionate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: fluticasone propionate"]},{"label":"azelastineHcl/fluticasone propionate","type":"EXPERIMENTAL","interventionNames":["Drug: azelastineHcl / fluticasone propionate"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"azelastine Hcl","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: azelastine Hcl"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"azelastine Hcl","otherNames":["azelastine"]},{"name":"azelastineHcl / fluticasone propionate","otherNames":["MP29-02"]},{"name":"fluticasone propionate","otherNames":["fluticasone"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female patients 12 years of age and older with a 2 year history of moderate to severe seasonal allergic rhinitis\n* Must be in generally good health\n* Must meet minimum symptom requirements, as specified in the protocol\n* Must be wiling and able to provide informed consent and to participate all study procedures\n* Positive skin test to a prevalent spring allergen\n\nExclusion criteria:\n\n* On nasal examination,the presence of nasal mucosal erosion, nasal ulceration or nasal septal perforation\n* Nasal disease likely to affect the deposition of the medication or evaluation, such as sinus infection, nasal polyps or severe deviated septum\n* Nasal or sinus surgery within the previous 6 months\n* Chronic sinus infection (more than 3 per year)\n* Planned travel outside the study area during the study period\n* Use of any investigational drug within 30 days of the first visit\n* Hypersensitivity (bad reaction) to azelastine hydrchloride nasal spray (Astelin), or fluticasone propionate nasal spray (Flonase)\n* Women who are not using an acceptable method or birth control\n* Women who are pregnant or nursing\n* Upper respiratory tract infection such as common cold, flu, sinus infection within 2 weeks of first study visit\n* Asthma or other lung diseases such as COPD. Mild asthma symptoms may be considered after consultation with the investigator\n* Irregular heartbeat or other symptomatic heart conditions\n* History of alcohol or drug abuse\n* History of glaucoma\n* Use of medications that could affect the study results","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (rTNSS)","description":"change from baseline in 12-hour reflective(how did you feel in the last 12 hours) total nasal symptom score (rTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.\n\nThe measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.The more negative value the better the result.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.6","spread":"5.2"},{"groupId":"OG001","value":"-4.7","spread":"4.7"},{"groupId":"OG002","value":"-4.2","spread":"4.6"},{"groupId":"OG003","value":"-2.9","spread":"3.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 12 Hour Instantaneous Total Nasal Symptom Score (iTNSS)","description":"change from baseline in 12-hour instantaneous ( how do you feel now) total nasal symptom score (iTNSS)consisting of nasal congestion,runny nose, itchy nose and sneezing scored twice daily (AM and PM) in diary cards for the entire 14 day study period.\n\nThe measurement scale is 0 to 24.A reduction in symptom severity score is indicated by a negative value.The more negative the value the better the result.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","spread":"5.3"},{"groupId":"OG001","value":"-4.5","spread":"4.7"},{"groupId":"OG002","value":"-4.0","spread":"4.7"},{"groupId":"OG003","value":"-2.6","spread":"4.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)at the End of 14 Days","description":"adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scored at day 1(baseline) and at day 14.\n\nThe scale is measured from a value of 0 to 24. A negative number corresponds to a change from baseline measurement.The more negative the value the better the result.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"1.4"},{"groupId":"OG001","value":"-1.6","spread":"1.2"},{"groupId":"OG002","value":"-1.4","spread":"1.1"},{"groupId":"OG003","value":"-0.9","spread":"1.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":207},"commonTop":["dysgusia","epistaxis","headache","nasal discomfort","nausea"]}}}